Prostate Cancer Reports

Volume 2 Supplement 3
 March 2014
Home > Prostate Cancer Reports > Volume 2 - Year 2014 > Supplement 3, March 2014


Diagnosis and evaluation
Etiology and pathogenesis
Integrative medicine
Overall management
Prognosis and outcome

Albert T, Pasquali R, Giusiano S, Roland G, Rossi D, Bastide C.
[Value of MRI in detection of extracapsular extension in prostate cancer: a prospective study comparing imaging and histology].
Prog Urol. 2014 Feb;24(2):102-7. doi: 10.1016/j.purol.2013.07.015. Epub 2013 Aug 30. French.
Abstract | Related citations

Vargas HA, Wassberg C, Fox JJ, Wibmer A, Goldman DA, Kuk D, Gonen M, Larson SM, Morris MJ, Scher HI, Hricak H.
Bone metastases in castration-resistant prostate cancer: associations between morphologic CT patterns, glycolytic activity, and androgen receptor expression on PET and overall survival.
Radiology. 2014 Apr;271(1):220-9. doi: 10.1148/radiol.13130625. Epub 2013 Nov 18.
Abstract | Related citations


Venkatasubramanian PN, Brendler CB, Plunkett BA, Crawford SE, Fitchev PS, Morgan G, Cornwell ML, McGuire MS, Wyrwicz AM, Doll JA.
Periprostatic adipose tissue from obese prostate cancer patients promotes tumor and endothelial cell proliferation: a functional and MR imaging pilot study.
Prostate. 2014 Feb;74(3):326-35.
Abstract | Related citations

Gonzales R.
New Study Reveals Four Nutrients that Lower PSA and Slow Cancer Progression.
Life Extension Magazine, 2013 Dec.
Abstract | Full text


Salomon L, Bastide C, Beuzeboc P, Cormier L, Fromont G, Hennequin C, Mongiat-Artus P, Peyromaure M, Ploussard G, Renard-Penna R, Rozet F, Azria D, Coloby P, Moliniť V, Ravery V, Rebillard X, Richaud P, Villers A, Souliť M; Les membres du CCAFU.
[CCAFU Recommendations 2013: Prostate cancer].
Prog Urol. 2013 Nov;23 Suppl 2:S69-101. doi: 10.1016/S1166-7087(13)70048-4. French.
Abstract | Full text | Related citations

Oncologic outcomes

Douard A, de la Taille A, Yiou R, Allory Y, Radulescu C, Vordos D, Hoznek A, Abbou CC, Salomon L.
[Prognostic impact of tumors localized at the prostatic apex].
Prog Urol. 2013 May;23(6):405-9. doi: 10.1016/j.purol.2013.02.003. Epub 2013 Mar 7. French.
Abstract | Related citations

Gleason score

Mulcahy N.
Gleason Grade Progression Is 'Uncommon'.
Medscape Medical News, 2013 Aug 14
Abstract | Full text

Treatment overviews

Petrylak DP.
Challenges in treating advanced disease.
Am J Manag Care. 2013 Dec;19(18 Suppl):s366-75.
Abstract | Full text | Related citations

Petrylak DP.
Current state of castration-resistant prostate cancer.
Am J Manag Care. 2013 Dec;19(18 Suppl):s358-65.
Abstract | Full text | Related citations


Advanced PCa

Chiang PH, Wang HC, Lai YL, Chen SC, Yen-Hwa W, Kok CK, Ou YC, Huang JS, Huang TC, Chao TY.
Zoledronic acid treatment for cancerous bone metastases: a phase IV study in Taiwan.
J Cancer Res Ther. 2013 Oct-Dec;9(4):653-9. doi: 10.4103/0973-1482.126471.
Abstract | Full text | Related citations

Goyal J, Antonarakis ES.
Clinical Evaluation of Abiraterone in the Treatment of Metastatic Prostate Cancer.
Clin Med Insights Urol. 2013 Jul 10;2013(7):1-14.
Abstract | Full text | Related citations

Takayama T, Sugiyama T, Furuse H, Yajima T, Suzuki T, Kai F, Nagata M, Otsuka A, Ishii Y, Ozono S.
[Salvage therapy for castration-refractory prostate cancer resistant to docetaxel].
Nihon Hinyokika Gakkai Zasshi. 2013 Nov;104(6):681-7.
Abstract | Related citations

Treatment comparison

Localized PCa

Thompson JE, Egger S, BŲhm M, Haynes AM, Matthews J, Rasiah K, Stricker PD.
Superior quality of life and improved surgical margins are achievable with robotic radical prostatectomy after a long learning curve: a prospective single-surgeon study of 1552 consecutive cases.
Eur Urol. 2014 Mar;65(3):521-31. doi: 10.1016/j.eururo.2013.10.030. Epub 2013 Oct 31.
Abstract | Full text | Related citations